Immunotherapeutic strategies for bladder cancer

Area of Science:

• Uro-oncology
• Immunotherapy
• Cancer Vaccines

Background:

• Bladder cancer is a common malignancy, often non-muscle-invasive at diagnosis with high recurrence rates.
• Bacillus Calmette-Guérin (BCG) immunotherapy is effective for high-risk bladder tumors but has limitations like adverse events and treatment failure.
• Novel immunotherapeutic strategies are needed to improve or replace current treatments for bladder cancer.

Purpose of the Study:

• To review clinical trials of therapeutic vaccination for bladder cancer using tumor-associated antigens.
• To discuss novel approaches for bladder cancer immunotherapy based on murine models.
• To highlight promising therapeutic vaccination strategies for non-muscle-invasive bladder cancer.

Main Methods:

• Review of clinical trials assessing therapeutic vaccination with tumor-associated antigens.
• Discussion of novel immunotherapeutic approaches derived from preclinical murine models.
• Analysis of vaccination routes and local immunostimulation for T-cell homing and recruitment.

Main Results:

• Current BCG therapy for bladder cancer has significant limitations, including adverse events and treatment failure.
• Therapeutic vaccination strategies are being explored as alternatives or adjuncts to BCG.
• Optimizing vaccination routes and local immunostimulation may enhance T-cell responses in the tumor microenvironment.

Conclusions:

• Improving or replacing current bladder cancer therapies with novel immunotherapeutic strategies is crucial.
• Therapeutic vaccination targeting tumor-associated antigens presents a promising avenue for non-muscle-invasive bladder cancer.
• Further research into vaccination routes and local immunostimulation is warranted to enhance efficacy.